Section 1: Introduction — The Kidney Doesn't Forgive

A consultation that happens every day

A 68-year-old man with type 2 diabetes and hypertension attends his primary care clinic in Kingston. His most recent creatinine is 142 µmol/L — mildly elevated, but nobody has calculated his eGFR. It is 38 mL/min. He has stage 3b chronic kidney disease and does not know it.

His medication list: metformin 1000 mg twice daily, gabapentin 300 mg three times daily for diabetic neuropathy, and colchicine 0.6 mg twice daily for a gout flare that started last week.

All three drugs require renal dose adjustment at his level of kidney function. None were adjusted.

Metformin at this dose in a patient with an eGFR of 38 carries a risk of lactic acidosis — rare but potentially fatal. Current guidelines permit metformin use down to eGFR 30 with dose reduction and monitoring, but 2000 mg daily is above the recommended maximum at this stage. Gabapentin accumulates in renal impairment, and at 900 mg daily with a CrCl under 60, the patient is at risk of excessive sedation, ataxia, and respiratory depression. Colchicine at full dose in a patient with CrCl under 30 can cause bone marrow suppression and neuromuscular toxicity.

This is not a rare case. It is a routine consultation with a routine medication list in a routine Caribbean primary care setting. The only thing missing was a calculation.

1.1 Why the Caribbean is particularly exposed

Chronic kidney disease prevalence in the Caribbean is among the highest in the Americas. The two leading causes — diabetes and hypertension — are the same two conditions that dominate Caribbean morbidity statistics. The Pan American Health Organisation has repeatedly identified CKD as a growing public health challenge in the region, driven by ageing populations, rising diabetes prevalence, and inconsistent screening.

The problem is not that Caribbean clinicians are unaware of renal dose adjustment. It is that the systems around them do not make it easy. Routine eGFR reporting is not universal in Caribbean laboratories. Where it is reported, it may not be prominently displayed or may be overlooked in a time-pressured consultation. Patients move between public and private facilities without a shared electronic record. Pharmacy dispensing systems do not routinely flag renal dose requirements. The result is that renal function is checked when someone thinks to check it, rather than as a matter of course.

Liver disease adds a second dimension. Hepatic impairment affects drug metabolism, but unlike renal impairment there is no single number that captures it. The Child-Pugh score — the standard clinical tool for grading hepatic function — requires five parameters (bilirubin, albumin, INR, ascites, encephalopathy) that are not always available in primary care. Many clinicians have no practical guidance on whether or how to adjust doses in hepatic impairment, and formulary references offer less granular hepatic dosing advice than renal.

The Caribbean context makes both problems worse. Hepatitis B prevalence is significant in several territories. Alcohol-related liver disease is common. Herbal hepatotoxicity — from preparations containing Aristolochia, kava kava, or comfrey — adds a dimension that international references rarely address. These are not exotic risks. They are everyday clinical realities in the region.

1.2 What this report covers

This is Report 2 in the ElesRx Clinical Reports series. Report 1, The Caribbean Clinical Interactions Atlas, mapped drug interactions, Beers Criteria flags, anticholinergic burden, prescribing cascades, and therapeutic duplications across Caribbean essential medicines. This report covers different ground entirely.

The focus here is organ function and dosing safety: what happens when a drug is prescribed at the wrong dose for a patient's kidney or liver.

Section 2 provides a brief overview of CKD in the Caribbean — prevalence, the diabetes-hypertension-CKD triangle, and the monitoring gap that allows renal impairment to go undetected.

Section 3 — the core of the report — profiles fifteen drugs commonly prescribed in the Caribbean that require renal dose adjustment, with specific thresholds, toxicities, and alternatives for each.

Section 4 gives the "triple whammy" — the combination of an ACE inhibitor or ARB, an NSAID, and a diuretic — its own dedicated section, because it is the single most preventable cause of acute kidney injury in Caribbean primary care and deserves more than a passing mention.

Section 5 addresses the harder problem of hepatic dosing — why there is no eGFR for the liver, how the Child-Pugh score works, and five hepatically-cleared drugs that Caribbean clinicians should know how to adjust.

Section 6 provides a monitoring checklist — a single table covering all twenty drugs in the report, designed to be printed and pinned to a clinic wall.

1.3 How to use this report

This report follows the same format as Report 1. Each section is self-contained. The drug profiles in Sections 3 and 5 are structured identically — drug name, what it is prescribed for, the renal or hepatic threshold that triggers adjustment, what happens if the dose is not adjusted, the correct adjusted dose or alternative, and a Caribbean Practice Note where relevant. Once you know one, you know them all.

The monitoring checklist in Section 6 is deliberately designed for print. It is a single table that fits on one page, listing every drug in the report alongside what to monitor, how often, and what triggers action. If your clinic has a wall, it belongs on that wall.

1.4 A note on methodology

The data in this report is drawn from the ElesRx clinical database, which contains renal and hepatic dosing grades for over 400 drugs. Dosing thresholds and adjustment recommendations are verified against DailyMed (US National Library of Medicine), the European Medicines Agency, Health Canada, LiverTox, and published clinical guidelines. The source hierarchy and licensing constraints are the same as Report 1 and are detailed in Section 8.

The clinical text in this report is original work. It has not been reproduced verbatim from any source. Where specific guidance is drawn from a particular reference, that reference is cited inline.

1.5 Before we begin

Every drug in this report is prescribed because it works. Metformin is the most effective first-line oral antidiabetic. Gabapentin provides real relief for neuropathic pain. Colchicine resolves gout flares. The point of this report is not to stop prescribing these drugs. It is to prescribe them at the right dose for the patient's kidney and liver — a distinction that requires nothing more than a calculation and a moment of attention.

The kidney does not forgive the dose you meant to adjust but didn't.

-e

Section 2: CKD in the Caribbean — The Numbers

2.1 The scale of the problem

Chronic kidney disease affects approximately one in ten adults globally.¹ In the Caribbean, the burden is higher. Latin America and the Caribbean carry among the highest mortality and disability-adjusted life years attributable to CKD worldwide, driven by the same conditions that dominate regional morbidity: diabetes, hypertension, and obesity.²

Jamaica illustrates the pattern clearly. CKD is the fourth leading cause of combined death and disability in the country, representing a 20% increase over the past decade.³ Modelled estimates from the Global Burden of Disease Study place CKD prevalence in Jamaica at 9–10%.³ A clinic-based study at the University Hospital of the West Indies Diabetes Clinic found that 22% of diabetic patients had an eGFR below 60 mL/min/1.73m², and 83% had elevated urine albumin excretion — both markers of established kidney disease.⁴ The Jamaica arm of the Caribbean Renal Registry includes more than 2,700 patients at various CKD stages, with over 800 receiving dialysis and 1,200 anticipated to need renal replacement therapy in the future.²

Trinidad and Tobago faces a similar trajectory. The country's high prevalence of type 2 diabetes (estimated at 12–14% of the adult population) and hypertension (approximately 26%) feeds directly into CKD incidence. End-stage renal disease rates have risen steadily, placing increasing pressure on the country's dialysis infrastructure.

The OECS member states — smaller populations with more constrained health systems — face the additional challenge that CKD often progresses undetected until advanced stages, because screening is inconsistent and specialist nephrology access is limited or absent on smaller islands.

2.2 The diabetes–hypertension–CKD triangle

The relationship between these three conditions is not linear — it is circular. Diabetes damages the kidneys. Hypertension damages the kidneys. Kidney damage worsens both diabetes management and blood pressure control, which in turn accelerates further kidney damage.

In the Caribbean, this triangle operates at population scale:

• One in three Jamaicans has hypertension. Twelve per cent have diabetes. Over 50% are overweight or obese.³
• Diabetes is the leading cause of CKD across the region, followed by hypertension and chronic glomerulonephritis.
• Many patients have both diabetes and hypertension simultaneously, compounding renal risk.

The drugs prescribed to manage diabetes and hypertension — metformin, sulfonylureas, ACE inhibitors, ARBs, diuretics — are themselves renally cleared or renally affected. This means that the very conditions that cause CKD also necessitate medications that require renal dose adjustment once CKD develops. The patient who needs the drug most is the patient most vulnerable to its misuse.

2.3 How CKD is staged

For clinicians who do not work with nephrology daily, a brief refresher on CKD staging is useful because the drug adjustment thresholds in Section 3 reference these stages directly.

CKD is staged by estimated glomerular filtration rate (eGFR), calculated from serum creatinine, age, and sex using the CKD-EPI equation:

The critical thresholds for drug dosing are eGFR 60 (where gabapentin, pregabalin, and baclofen adjustments begin), eGFR 45–50 (where digoxin, cimetidine, and H2 antagonists need reduction), and eGFR 30 (where metformin, duloxetine, colchicine, enoxaparin, and many others become high-risk or contraindicated).

Two important practical points:

Creatinine clearance (CrCl) is not the same as eGFR. For most drugs, eGFR is an acceptable surrogate. For DOACs (dabigatran, rivaroxaban, apixaban, edoxaban), enoxaparin, and other narrow therapeutic index drugs, CrCl calculated by the Cockcroft-Gault equation should be used, because eGFR can overestimate renal function — particularly in elderly patients and those with low muscle mass. Using eGFR instead of CrCl for DOAC dosing is a documented source of bleeding complications.

A "normal" serum creatinine does not mean normal kidney function. An older adult with reduced muscle mass can have a serum creatinine within the laboratory reference range while their actual GFR is significantly impaired. This is why eGFR (which accounts for age and sex) is more reliable than creatinine alone — and why a creatinine result without an eGFR calculation is clinically incomplete.

2.4 The monitoring gap

The drugs in Section 3 all have clear, published dose adjustment thresholds. The clinical problem is not knowledge — it is workflow. Renal function is not checked, or is checked but not calculated, or is calculated but not linked to the prescribing decision.

Several structural factors contribute to this gap in Caribbean practice:

eGFR is not universally reported by Caribbean laboratories. Some laboratories report serum creatinine without calculating eGFR, leaving the clinician to perform the calculation themselves. In a busy clinic, this calculation is often skipped.

Renal function is checked episodically, not continuously. A patient's eGFR may have been 65 two years ago and is now 38, but if no repeat test has been ordered, the clinician is prescribing to a kidney function that no longer exists.

Polypharmacy obscures the problem. A patient on eight medications is unlikely to have each one individually cross-referenced against their most recent renal function. The drug that was safe at eGFR 65 may no longer be safe at eGFR 42, but the prescription continues unchanged because nobody rechecked.

Multiple prescribers compound the risk. A hospital physician starts gabapentin. A primary care clinician continues it. Neither checks whether the current dose matches the patient's current renal function.

The monitoring checklist in Section 6 is designed to address this gap at the clinic level — a practical, printable reference that links each drug to the test required, the frequency, and the threshold for action.

References for this section:

¹ GBD 2023 CKD Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023. Lancet. 2025. doi:10.1016/S0140-6736(25)01853-7

² Ferguson TS, Tulloch-Reid MK, Younger-Coleman NO, et al. The burden of chronic kidney disease and its major risk factors in Jamaica. Kidney Int. 2018;94(5):S27–S28. doi:10.1016/j.kint.2018.08.016

³ Cunningham-Myrie CA, et al. Chronic kidney disease in Jamaica: estimated prevalence and associated risk factors from the Jamaica Health and Lifestyle Survey III. medRxiv. 2025. doi:10.1101/2025.03.31.25324786

⁴ Waugh NR, et al. Prevalence of chronic kidney disease among patients attending a specialist diabetes clinic in Jamaica. West Indian Med J. 2013;62(7):632–637. PMC4763891 -e

Section 3: The Fifteen Drugs That Don't Forgive

These are fifteen drugs commonly prescribed in Caribbean primary care that require renal dose adjustment — and that routinely do not receive it. Each profile follows the same structure: what the drug is prescribed for, the renal threshold that triggers adjustment, what happens if the dose is not adjusted, the correct adjusted dose or alternative, and a Caribbean Practice Note where relevant.

The renal grades for each drug are drawn from the ElesRx database and verified against DailyMed, EMA, and Health Canada labelling.

3.1 Metformin

Prescribed for: Type 2 diabetes mellitus — first-line oral agent across all Caribbean formularies.

Renal threshold: eGFR 30 mL/min. Current guidelines permit use down to eGFR 30 with dose reduction (maximum 1000 mg/day). Contraindicated below eGFR 30.

What happens if not adjusted: Lactic acidosis — rare but potentially fatal. The risk increases as metformin accumulates in renal impairment, particularly in the presence of dehydration, sepsis, or acute illness. Symptoms are non-specific (nausea, abdominal pain, malaise, hyperventilation) and easily attributed to other causes.

Adjusted dose: eGFR 30–44: maximum 1000 mg/day, reassess renal function every 3 months. eGFR 45–59: maximum 2000 mg/day, reassess every 3–6 months. Below eGFR 30: discontinue.

Caribbean Practice Note: Metformin is the most widely prescribed oral antidiabetic in the Caribbean and is often started at full dose (2000 mg/day) without checking renal function. The historic blanket contraindication below eGFR 60 has been relaxed, but the new guidance — use with dose reduction down to eGFR 30 — requires monitoring that is not always in place. A patient on metformin should have their eGFR checked at least annually, and more frequently if it is declining.

3.2 Gabapentin

Prescribed for: Neuropathic pain (particularly diabetic neuropathy), post-herpetic neuralgia, adjunctive epilepsy treatment.

Renal threshold: CrCl 60 mL/min. Dose reduction required at all stages below this.

What happens if not adjusted: Gabapentin is almost entirely renally cleared. Accumulation causes excessive sedation, dizziness, ataxia, cognitive impairment, and — in severe cases — respiratory depression. These symptoms are often attributed to the patient's age or underlying condition rather than to drug accumulation.

Adjusted dose: CrCl 30–59: 200–700 mg/day. CrCl 15–29: 100–300 mg/day. CrCl <15: 100–300 mg every other day. Post-haemodialysis: supplemental dose of 125–350 mg.

Caribbean Practice Note: Gabapentin is increasingly prescribed in the Caribbean for neuropathic pain, partly as a safer alternative to opioids. The standard starting dose of 300 mg three times daily (900 mg/day) is appropriate for patients with normal renal function but is too high for any patient with CrCl below 60. In the diabetic patient — who is at risk of both neuropathy and CKD — this mismatch is common.

3.3 Pregabalin

Prescribed for: Neuropathic pain, generalised anxiety disorder, fibromyalgia, adjunctive epilepsy treatment.

Renal threshold: CrCl 60 mL/min. Dose reduction required at all stages below this.

What happens if not adjusted: Same profile as gabapentin — sedation, dizziness, ataxia, cognitive impairment, peripheral oedema. Pregabalin accumulates rapidly in renal impairment because it is almost entirely renally excreted unchanged.

Adjusted dose: CrCl 30–60: 75–300 mg/day (in 2–3 divided doses). CrCl 15–30: 25–150 mg/day. CrCl <15: 25–75 mg/day. Post-haemodialysis: supplemental dose.

Caribbean Practice Note: Pregabalin is prescribed less frequently than gabapentin in Caribbean primary care (partly due to cost), but where it is used, the same renal adjustment gap applies. Patients switched from gabapentin to pregabalin for perceived better efficacy should have their renal function checked at the time of switching, as the dose conversion must account for both drug potency and renal clearance.

3.4 Colchicine

Prescribed for: Acute gout, gout prophylaxis, familial Mediterranean fever.

Renal threshold: CrCl 30 mL/min. Dose reduction required; some guidelines contraindicate repeat dosing below CrCl 30.

What happens if not adjusted: Colchicine toxicity is multi-system: bone marrow suppression (pancytopenia), neuromuscular toxicity (myopathy, neuropathy), and gastrointestinal toxicity (severe diarrhoea, vomiting). In severe renal impairment, toxicity can occur at standard doses and can be fatal. The therapeutic window is narrow, and toxicity mimics other conditions — making delayed recognition common.

Adjusted dose: CrCl 30–50: reduce dose by 50% and avoid repeated courses within 14 days. CrCl <30: contraindicated for acute treatment; if prophylaxis is required, use 0.3 mg every other day with close monitoring.

Caribbean Practice Note: Gout is common in the Caribbean, and colchicine is the standard acute treatment. It is frequently prescribed at full dose (0.6 mg twice daily or the older 0.5 mg hourly regimen) without any renal check. In a patient with unrecognised CKD — particularly one taking a thiazide diuretic that has itself raised uric acid levels (see Report 1, Cascade 5) — colchicine toxicity is a real and preventable risk.

3.5 Digoxin

Prescribed for: Atrial fibrillation (rate control), heart failure.

Renal threshold: CrCl 50 mL/min. Dose reduction and therapeutic drug monitoring required.

What happens if not adjusted: Digoxin has a narrow therapeutic index. In renal impairment, reduced clearance leads to accumulation and toxicity: nausea, visual disturbance (yellow-green halos), confusion, and — critically — cardiac arrhythmias (bradycardia, heart block, ventricular tachycardia). Digoxin toxicity is a medical emergency and can be fatal.

Adjusted dose: In older adults, do not exceed 0.125 mg/day regardless of renal function (per Beers Criteria). In CKD with CrCl <50: start at 0.0625 mg/day or every other day. Monitor serum digoxin levels (target 0.5–0.9 ng/mL for AF and heart failure). Check potassium — hypokalaemia increases digoxin toxicity.

Caribbean Practice Note: Digoxin remains widely used in Caribbean practice for both atrial fibrillation and heart failure. The combination of digoxin with a loop diuretic (furosemide) — extremely common in these patients — creates a dual risk: the diuretic lowers potassium, and low potassium potentiates digoxin toxicity. Any patient on digoxin and a diuretic should have both renal function and potassium monitored regularly.

3.6 Enoxaparin

Prescribed for: VTE treatment and prophylaxis, acute coronary syndromes, post-surgical thromboprophylaxis.

Renal threshold: CrCl 30 mL/min. Dose reduction required.

What happens if not adjusted: Enoxaparin is renally cleared. Accumulation increases anti-Xa activity beyond the therapeutic range, leading to major bleeding — including intracranial haemorrhage, gastrointestinal bleeding, and wound haematomas. The risk is highest in elderly patients with unrecognised renal impairment.

Adjusted dose: CrCl ≥30: standard dosing (1 mg/kg BD for treatment, 40 mg OD for prophylaxis). CrCl <30: reduce to 1 mg/kg OD for treatment, 30 mg OD for prophylaxis. Consider unfractionated heparin instead if CrCl is very low or unstable.

Caribbean Practice Note: Enoxaparin is used routinely in Caribbean hospitals for VTE prophylaxis and treatment. The dose reduction at CrCl <30 is well-established in guidelines but inconsistently applied, particularly when patients are admitted to surgical wards where renal function may not be rechecked after the initial assessment. Elderly post-surgical patients are the highest-risk group.

3.7 Dabigatran

Prescribed for: Non-valvular atrial fibrillation, VTE treatment and prevention.

Renal threshold: CrCl 50 mL/min for dose consideration; CrCl 30 for dose reduction; contraindicated below CrCl 15.

What happens if not adjusted: Dabigatran is approximately 80% renally excreted. Accumulation leads to excessive anticoagulation and major bleeding. Unlike warfarin, routine monitoring is not standard, so over-anticoagulation may go undetected until a bleeding event occurs. A specific reversal agent (idarucizumab) exists but may not be available in all Caribbean hospitals.

Adjusted dose: CrCl >50: 150 mg BD (standard). CrCl 30–50: 150 mg BD (standard), but reduce to 75 mg BD if co-prescribed with P-gp inhibitors (dronedarone, ketoconazole). CrCl 15–30: 75 mg BD. CrCl <15: no recommendation — avoid.

Caribbean Practice Note: DOACs are increasingly prescribed in the Caribbean as alternatives to warfarin for AF and VTE. Dabigatran's renal dependence makes it the most sensitive of the DOACs to kidney function. For patients with CKD, apixaban — which is only 27% renally cleared — may be a safer choice. The critical point is that all DOACs require CrCl (not eGFR) for dosing decisions, and this calculation should be performed at initiation and at least annually thereafter.

3.8 Allopurinol

Prescribed for: Chronic gout (urate-lowering therapy), hyperuricaemia.

Renal threshold: CrCl 60 mL/min. Start at reduced dose and titrate slowly.

What happens if not adjusted: Allopurinol hypersensitivity syndrome — a severe, potentially fatal reaction characterised by fever, rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis), eosinophilia, hepatitis, and renal failure. The risk is highest when allopurinol is started at standard doses (300 mg/day) in patients with renal impairment. Hypersensitivity is also associated with the HLA-B*5801 allele, which has elevated prevalence in populations of African descent — directly relevant to Caribbean demographics.

Adjusted dose: CrCl >60: start at 100 mg/day, titrate by 100 mg every 2–4 weeks to target urate. CrCl 30–60: start at 50 mg/day. CrCl <30: start at 50 mg every other day. Never start at 300 mg/day in any patient.

Caribbean Practice Note: Allopurinol is the standard urate-lowering therapy across the Caribbean. The practice of starting at 300 mg/day — still common — predates current understanding of hypersensitivity risk. In a Caribbean patient population with elevated HLA-B*5801 prevalence and high rates of undiagnosed CKD, the combination of full-dose initiation and unrecognised renal impairment creates a preventable risk of a serious and sometimes fatal reaction. Start low, go slow, and check renal function first.

3.9 Spironolactone

Prescribed for: Heart failure, resistant hypertension, ascites (hepatic), primary aldosteronism.

Renal threshold: eGFR 30 mL/min; doses above 25 mg/day carry hyperkalaemia risk at any level of renal impairment.

What happens if not adjusted: Spironolactone is a potassium-sparing diuretic. In renal impairment, potassium excretion is already impaired. Adding spironolactone — or continuing it at standard doses as renal function declines — can cause life-threatening hyperkalaemia: muscle weakness, cardiac arrhythmias, and cardiac arrest. The risk is compounded by co-prescription of ACE inhibitors or ARBs, which also raise potassium.

Adjusted dose: eGFR >30: use with caution at doses above 25 mg/day; monitor potassium within 1 week of starting and after any dose change. eGFR <30: avoid unless under specialist supervision. Always check potassium before starting and monitor regularly.

Caribbean Practice Note: Spironolactone is commonly prescribed in the Caribbean for heart failure (in combination with ACE inhibitors and diuretics) and for resistant hypertension. The triple combination of ACE inhibitor + spironolactone + declining renal function is a well-known setup for hyperkalaemia. Potassium monitoring is the intervention — and it is frequently omitted.

3.10 Baclofen

Prescribed for: Spasticity (multiple sclerosis, spinal cord injury, cerebral palsy), occasionally for alcohol withdrawal.

Renal threshold: eGFR 60 mL/min. Avoid if eGFR <60 unless no alternative exists.

What happens if not adjusted: Baclofen is predominantly renally cleared. Accumulation in renal impairment causes encephalopathy — confusion, drowsiness, respiratory depression, and in severe cases, coma requiring hospitalisation. Cases of baclofen toxicity requiring ICU admission have been reported in patients with unrecognised renal impairment.

Adjusted dose: eGFR ≥60: standard dosing (5 mg TDS, titrate to effect). eGFR 30–59: reduce dose by 50%; use lowest effective dose. eGFR <30: avoid; if absolutely required, use 5 mg OD with close monitoring.

Caribbean Practice Note: Baclofen is used in the Caribbean primarily for spasticity. Its renal clearance is not widely appreciated, and it may be continued at standard doses in patients whose renal function has declined since the drug was first prescribed. Any patient on baclofen who develops unexplained drowsiness or confusion should have their renal function checked before attributing the symptoms to disease progression.

3.11 Duloxetine

Prescribed for: Depression, generalised anxiety disorder, diabetic neuropathic pain, fibromyalgia.

Renal threshold: CrCl 30 mL/min. Avoid below this threshold.

What happens if not adjusted: Duloxetine and its metabolites accumulate in severe renal impairment, increasing GI adverse effects (nausea, diarrhoea) and the risk of hepatotoxicity. The drug is also associated with hyponatraemia, which is compounded by renal impairment.

Adjusted dose: CrCl ≥30: standard dosing (60 mg/day). CrCl <30: avoid. If an SNRI is needed in severe renal impairment, venlafaxine (with dose reduction) may be considered, though it also requires adjustment.

Caribbean Practice Note: Duloxetine is increasingly prescribed in the Caribbean for diabetic neuropathic pain as an alternative to amitriptyline (which carries high anticholinergic burden — see Report 1). In the diabetic patient who also has CKD, the prescriber faces a genuine dilemma: amitriptyline is Beers-flagged, gabapentin needs renal adjustment, and duloxetine is contraindicated below CrCl 30. The answer is often gabapentin at an adjusted dose, but the choice requires knowing the patient's renal function.

3.12 Tramadol

Prescribed for: Moderate-to-severe pain, particularly where NSAIDs are contraindicated.

Renal threshold: CrCl 30 mL/min. Dose reduction and interval extension required.

What happens if not adjusted: Tramadol and its active metabolite (O-desmethyltramadol) accumulate in renal impairment, increasing the risk of seizures, respiratory depression, serotonin syndrome, and hypoglycaemia. The hypoglycaemia risk is particularly insidious — it can occur days after starting the drug and is easily missed in a diabetic patient whose glucose is attributed to their diabetes management.

Adjusted dose: CrCl ≥30: standard dosing (50–100 mg every 4–6 hours, max 400 mg/day). CrCl <30: immediate-release only; 50 mg every 12 hours; max 200 mg/day. Extended-release tramadol should not be used if CrCl <30.

Caribbean Practice Note: Tramadol is widely used in the Caribbean as a "step 2" analgesic, partly because it is perceived as less risky than stronger opioids. In the patient with CKD, this perception is misleading. The seizure risk is real, and the hypoglycaemia risk in diabetic patients — the very patients most likely to have CKD — is underappreciated. If tramadol is used in CKD, the dose must be reduced and the patient monitored for both neurological and metabolic adverse effects.

3.13 Ciprofloxacin

Prescribed for: Urinary tract infections, lower respiratory infections, bone and joint infections, gastroenteritis.

Renal threshold: CrCl 30 mL/min. Dose reduction required.

What happens if not adjusted: Ciprofloxacin accumulates in renal impairment, increasing the risk of CNS toxicity (seizures, confusion, hallucinations), crystalluria (urinary crystal formation leading to renal damage), and tendon rupture. QT prolongation risk is also increased, particularly in combination with other QT-prolonging agents.

Adjusted dose: CrCl ≥30: standard dosing. CrCl <30: reduce dose by 50% (e.g., 250 mg BD instead of 500 mg BD). For severe infections requiring higher doses, extend the interval rather than increasing the dose.

Caribbean Practice Note: Ciprofloxacin is one of the most commonly prescribed antibiotics in the Caribbean, used broadly for urinary, respiratory, and gastrointestinal infections. The renal adjustment threshold of CrCl 30 is well-established but may be overlooked in the acute setting — a patient presenting with a UTI may have their antibiotic prescribed and dispensed without any renal function check, particularly in busy public clinics.

3.14 Famotidine (and H2-receptor antagonists)

Prescribed for: Peptic ulcer disease, GORD, dyspepsia, gastroprotection.

Renal threshold: CrCl 50 mL/min. Dose reduction required.

What happens if not adjusted: H2-receptor antagonists (famotidine, cimetidine, nizatidine) are renally cleared. Accumulation causes mental status changes — confusion, agitation, hallucinations — particularly in elderly patients. Cimetidine carries the additional risk of drug interactions (CYP inhibition) and gynaecomastia. These CNS effects are often misattributed to dementia or delirium from other causes.

Adjusted dose: CrCl 30–50: reduce dose by 50% or extend interval to once daily. CrCl <30: reduce dose by 75% or use every 36–48 hours. Consider whether the H2 antagonist is still needed — many patients are on both an H2 antagonist and a PPI simultaneously, which is therapeutic duplication.

Caribbean Practice Note: Famotidine and ranitidine (where still available) are commonly dispensed in the Caribbean, often over the counter. Patients may be self-medicating without their clinician's knowledge. In elderly patients with CKD presenting with new-onset confusion, H2 antagonist accumulation should be on the differential diagnosis — and a medication history that includes OTC purchases is essential.

3.15 Amiloride (and Triamterene)

Prescribed for: Oedema, hypertension (usually in combination with a thiazide), hypokalaemia prevention.

Renal threshold: CrCl 30 mL/min. Avoid below this threshold.

What happens if not adjusted: Amiloride and triamterene are potassium-sparing diuretics. In renal impairment, potassium retention is already impaired. These drugs compound the problem, leading to hyperkalaemia — muscle weakness, paraesthesia, cardiac arrhythmias, and potentially cardiac arrest. The risk is magnified by co-prescription of ACE inhibitors, ARBs, or spironolactone.

Adjusted dose: CrCl ≥30: standard dosing with potassium monitoring. CrCl <30: avoid. If a diuretic is needed in severe CKD, use a loop diuretic (furosemide) which does not cause potassium retention.

Caribbean Practice Note: Fixed-dose combination tablets of hydrochlorothiazide + amiloride (or hydrochlorothiazide + triamterene) are widely available in Caribbean pharmacies, sometimes as the only diuretic formulation in stock. Clinicians may not realise that the combination tablet contains a potassium-sparing component, particularly if the prescription or dispensing label lists only the brand name. In CKD, the potassium-sparing component is the dangerous part.

-e

Section 4: The Triple Whammy

The single most preventable acute kidney injury in Caribbean primary care

The term "triple whammy" refers to the concurrent use of three drug classes:

1. An ACE inhibitor or ARB (lisinopril, enalapril, ramipril, losartan, valsartan, telmisartan)
2. A diuretic (furosemide, hydrochlorothiazide, indapamide, spironolactone)
3. An NSAID (diclofenac, ibuprofen, naproxen, meloxicam, indomethacin)

Each class alone is safe in most patients. Together, they create a convergent assault on renal blood flow that can precipitate acute kidney injury (AKI) — sometimes within days of the third drug being added.

4.1 The pharmacology, simply explained

The kidney maintains its filtration rate by balancing two blood vessels:

The afferent arteriole brings blood into the glomerulus. It dilates under the influence of prostaglandins — the same prostaglandins that NSAIDs inhibit.

The efferent arteriole carries blood out of the glomerulus. It constricts under the influence of angiotensin II — which ACE inhibitors and ARBs block.

In a healthy, well-hydrated patient, blocking one of these systems has a manageable effect. The kidney compensates. But when both systems are blocked simultaneously:

• The NSAID constricts the afferent arteriole (by inhibiting prostaglandin-mediated vasodilation). Less blood enters the glomerulus.
• The ACE inhibitor or ARB dilates the efferent arteriole (by blocking angiotensin II). Blood exits the glomerulus too easily.
• The diuretic reduces circulating volume. There is less blood to begin with.

The result: filtration pressure drops below the threshold needed to maintain GFR. The kidneys stop filtering effectively. Creatinine rises. If the situation is not recognised and reversed — by stopping the NSAID and holding the diuretic — the patient progresses to established AKI requiring hospitalisation.

4.2 How often it happens

The triple whammy is not a theoretical risk. A landmark Australian study by Lapi and colleagues (2013) found that the combination of a diuretic, an ACE inhibitor or ARB, and an NSAID was associated with a 31% increased risk of acute kidney injury compared to dual therapy with a diuretic and ACE/ARB alone. The risk was highest in the first 30 days of concurrent use.⁵

In Caribbean practice, the conditions for this combination are present at every clinic visit:

• ACE inhibitors and diuretics are the backbone of hypertension and heart failure management across the region.
• NSAIDs are available over the counter in every Caribbean pharmacy. Patients add ibuprofen or diclofenac for pain without informing their clinician.
• Many patients are already volume-depleted — from tropical heat, inadequate fluid intake, or from the diuretic itself.

The patient who walks into a Caribbean pharmacy and buys ibuprofen over the counter while already taking lisinopril and hydrochlorothiazide has just completed the triple whammy. Nobody in the chain — the patient, the pharmacist, the prescribing clinician — may be aware of it.

4.3 The clinical scenario

Patient profile: 73-year-old woman with hypertension and mild heart failure. Current medications: enalapril 10 mg daily, furosemide 40 mg daily.

What happens: The patient develops knee pain from osteoarthritis. She purchases diclofenac 50 mg from the pharmacy and takes it twice daily for a week. By day five, she is dizzy and nauseated. By day eight, she presents to the emergency department with a creatinine of 380 µmol/L (baseline 110). She has acute kidney injury.

What should have happened: Before adding any NSAID to a patient on an ACE inhibitor and a diuretic, renal function should be checked. In most cases, the NSAID should be avoided entirely and an alternative analgesic used — paracetamol, topical NSAIDs (where available), or referral for physiotherapy. If a short-course NSAID is deemed essential, it should be the lowest dose for the shortest duration, with renal function checked within 48–72 hours and the diuretic temporarily held.

4.4 Why the NSAID is usually the problem

In most triple whammy cases, the ACE inhibitor and the diuretic were prescribed intentionally and appropriately for an established condition. The NSAID was added later — often by the patient themselves, often without the prescribing clinician's knowledge, and often without any renal function check.

The clinical intervention is therefore simple:

• Ask every patient on an ACE inhibitor or ARB + diuretic whether they use NSAIDs — including over-the-counter purchases.
• Educate the patient that ibuprofen and diclofenac interact with their existing medications and should not be taken without consulting their clinician.
• Use paracetamol as the default analgesic in these patients. Paracetamol does not affect renal blood flow.
• If an NSAID is essential, use the lowest dose for the shortest duration, hold the diuretic if clinically safe, and check renal function within 48–72 hours.

4.5 How ElesRx flags this

When a clinician enters a medication list containing an ACE inhibitor or ARB, a diuretic, and an NSAID, ElesRx flags the triple whammy as a major interaction with a specific alert explaining the renal mechanism and the clinical action required. The system also checks the patient's renal function (if entered) and escalates the alert severity if eGFR is already impaired.

This combination is one of the most common alerts in the ElesRx interaction database — because it is one of the most commonly prescribed combinations in the region.

⁵ Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi:10.1136/bmj.e8525 -e

Section 5: The Liver Problem — Why Hepatic Dosing Is Harder

5.1 There is no eGFR for the liver

Renal dosing is relatively straightforward because we have a single number — eGFR — that captures kidney function with reasonable accuracy. Liver function has no equivalent. Serum creatinine maps to GFR. There is no single blood test that maps to the liver's drug-metabolising capacity.

The standard clinical tool for grading hepatic impairment is the Child-Pugh score, which combines five parameters:

Child-Pugh A (5–6 points) = mild impairment. Child-Pugh B (7–9) = moderate. Child-Pugh C (10–15) = severe.

The practical problem in Caribbean primary care is that calculating a Child-Pugh score requires five pieces of information — bilirubin, albumin, INR, ascites assessment, and encephalopathy grading — that are not always available in a single visit, particularly in a primary care setting. Renal function can be estimated from a single creatinine result. Hepatic function cannot.

This does not mean hepatic dosing can be ignored. It means clinicians need to know which drugs are hepatically cleared and what the risks of standard dosing are in liver disease — even if the grading is less precise than for renal impairment.

5.2 Liver disease in the Caribbean context

Three patterns of liver disease are particularly relevant to Caribbean prescribing:

Hepatitis B. Prevalence of chronic hepatitis B varies across Caribbean territories but is significant in several, particularly in Haiti, the Dominican Republic, and among migrant populations within CARICOM. Patients with chronic hepatitis B may have subclinical hepatic impairment that affects drug metabolism without producing obvious symptoms.

Alcohol-related liver disease. Alcohol consumption patterns in the Caribbean contribute to a meaningful burden of alcoholic hepatitis and cirrhosis, often undiagnosed until advanced stages. A patient with early alcoholic liver disease may have no symptoms but reduced hepatic metabolising capacity.

Herbal hepatotoxicity. As discussed in Report 1, certain herbal preparations used in Caribbean traditional medicine — particularly those containing Aristolochia, kava kava, and comfrey — are directly hepatotoxic. Patients using these preparations alongside hepatically-cleared medications face a double risk: the herb damages the liver, and the damaged liver cannot clear the medication.

5.3 Five hepatic drugs to watch

1. Paracetamol

Why it matters: Paracetamol is the most commonly used analgesic and antipyretic in the Caribbean. It is also the most common cause of acute liver failure worldwide when taken in overdose. In patients with pre-existing hepatic impairment, the maximum safe daily dose is lower than the standard 4 g/day.

Hepatic grades in ElesRx: Mild: use with caution. Moderate: reduce dose. Severe: contraindicated.

Adjusted dose: In hepatic impairment: maximum 2 g/day (500 mg QDS or 1 g BD). In severe hepatic impairment or active liver disease: avoid. Avoid co-administration with other hepatotoxic agents.

Caribbean Practice Note: Paracetamol is available over the counter everywhere in the Caribbean. Patients with liver disease may not realise that the "safe" analgesic they take daily carries hepatic risk at standard doses. Clinicians should explicitly counsel patients with known liver disease on their maximum daily paracetamol dose.

2. Methotrexate

Why it matters: Methotrexate is used in the Caribbean for rheumatoid arthritis, psoriasis, and some oncology indications. It is inherently hepatotoxic — cumulative hepatic fibrosis is a known long-term complication, and liver function must be monitored throughout treatment.

Hepatic grades in ElesRx: Mild: use with caution. Moderate: use with caution. Severe: use with caution.

Monitoring required: LFTs before starting and every 1–2 months during treatment. If ALT rises to more than twice the upper limit of normal, hold methotrexate and recheck. If persistently elevated, discontinue. Liver biopsy may be considered for cumulative dose monitoring in long-term use.

Caribbean Practice Note: Methotrexate monitoring requires regular blood tests — FBC, LFTs, and renal function — at intervals that may be difficult to maintain in resource-constrained settings. Patients on methotrexate who are lost to follow-up for several months are at risk of undetected hepatic (and haematological) toxicity. The drug should not be prescribed without a clear plan for monitoring, and the patient should understand the commitment involved.

3. Amiodarone

Why it matters: Amiodarone is used for both atrial and ventricular arrhythmias. It is one of the most broadly toxic drugs in routine clinical use, affecting the thyroid, lungs, liver, eyes, and peripheral nerves. Hepatotoxicity occurs in up to 1% of patients annually and can range from asymptomatic enzyme elevation (15–50% of long-term users) to fatal hepatic failure.

Hepatic grades in ElesRx: Mild: use with caution. Moderate: use with caution. Severe: contraindicated.

Monitoring required: LFTs before starting and every 6 months during treatment. If transaminases exceed three times the upper limit of normal, reduce dose or discontinue. Amiodarone has an extremely long half-life (40–55 days), so hepatotoxicity can persist for months after the drug is stopped.

Caribbean Practice Note: Amiodarone is flagged by the Beers Criteria (Report 1, Section 4) for multiple toxicities in older adults. In Caribbean practice, where thyroid and liver monitoring may not be performed at the recommended frequency, the drug's long-term risks are amplified. If a patient on amiodarone develops fatigue, nausea, or weight loss, hepatic toxicity should be considered even if the drug was started years ago.

4. Atorvastatin

Why it matters: Statins are the most prescribed lipid-lowering agents globally and are widely used in the Caribbean. Atorvastatin is hepatically metabolised and is contraindicated in active liver disease. While statin-induced liver injury is rare, it is more likely in patients with pre-existing hepatic impairment, high alcohol intake, or concurrent use of other hepatotoxic drugs.

Hepatic grades in ElesRx: Mild: use with caution. Moderate: contraindicated. Severe: contraindicated.

Monitoring required: LFTs before starting. Routine monitoring during treatment is no longer universally recommended (FDA removed this requirement in 2012), but LFTs should be checked if symptoms of liver injury develop (fatigue, anorexia, dark urine, jaundice).

Caribbean Practice Note: Atorvastatin is commonly prescribed alongside other hepatically-metabolised drugs (amlodipine, omeprazole, amiodarone) in Caribbean patients with cardiovascular disease. The cumulative hepatic load should be considered, particularly in patients with alcohol use or known hepatic steatosis (fatty liver disease, increasingly common with obesity and diabetes).

5. Isoniazid

Why it matters: Isoniazid is a cornerstone of tuberculosis treatment and prophylaxis. It is also one of the most common causes of drug-induced liver injury worldwide. Hepatotoxicity occurs in 10–20% of patients (as asymptomatic enzyme elevation) and progresses to clinical hepatitis in 1–2%. Risk increases with age, alcohol use, pre-existing liver disease, and concurrent hepatotoxic drugs.

Hepatic grades in ElesRx: All stages: no specific dose adjustment data — use with caution and monitor.

Monitoring required: LFTs before starting, then monthly for the first 3 months and periodically thereafter. If ALT exceeds 3 times the upper limit of normal with symptoms (or 5 times without symptoms), hold isoniazid. Resume at a lower dose or discontinue depending on the clinical context.

Caribbean Practice Note: TB remains a public health concern in several Caribbean territories, and isoniazid is used for both treatment (in combination) and latent TB prophylaxis (as monotherapy for 6–9 months). The hepatotoxicity risk is highest when isoniazid is combined with other hepatotoxic agents — including rifampicin, which is part of the standard TB regimen, and alcohol, which is common in the same populations at risk for TB. Monthly LFT monitoring for the first 3 months of isoniazid therapy is essential and should not be skipped.

Section 6: The Monitoring Checklist

What to check, how often, and when to act

The following table covers all twenty drugs profiled in Sections 3 and 5. It is designed to be printed on a single page and posted in a clinic or pharmacy.

Renal drugs — check eGFR or CrCl

Hepatic drugs — check LFTs

One rule for the wall: Before prescribing any of these drugs, check the relevant organ function. Before continuing them, recheck it.

Section 7: About ElesRx

Every renal and hepatic flag in this report — every eGFR threshold, every dose adjustment, every monitoring requirement — is built into ElesRx and fires automatically when a clinician enters a patient's medication list alongside their renal function or Child-Pugh score.

ElesRx is a clinical decision support tool built for Caribbean clinicians. Enter a medication list and patient context, and ElesRx returns renal dosing flags, hepatic adjustment warnings, drug interactions, ElderWatch™ alerts (Beers Criteria), anticholinergic burden scoring, prescribing cascade detection, and therapeutic duplicate identification — in a single analysis.

The free tier supports up to three saved patient profiles. Full access is $9.99 per month.

elesrx.com

ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 8: Methodology and References

8.1 Data sources

Renal and hepatic dosing grades in this report are drawn from the ElesRx clinical database (pharmacoai), which contains renal grades (mild, moderate, severe, ESRD) and hepatic grades (mild, moderate, severe) for over 400 drugs. Grades are verified against:

Sources explicitly excluded: DrugBank (commercial licence required) and WHO Essential Medicines List (CC BY-NC-SA, non-commercial only).

8.2 Clinical staging references

Renal staging follows KDIGO 2012 guidelines (eGFR-based CKD staging). Creatinine clearance references use the Cockcroft-Gault equation as per original pharmacokinetic studies. Hepatic staging follows the Child-Pugh classification.

8.3 Limitations

This report profiles twenty drugs. The ElesRx database contains renal and hepatic grades for over 400. The twenty were selected for their prevalence in Caribbean prescribing and the clinical significance of their dose adjustment requirements. They are not exhaustive.

Drug availability, pricing, and regulatory status vary across Caribbean territories. Recommendations regarding alternatives should be confirmed against local formulary access.

This report is not a substitute for clinical judgement. All prescribing decisions should be made in the context of the individual patient.

8.4 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published freely and without an access gate as a contribution to Caribbean clinical education. No external funding was received.

8.5 Citation

Duncan J. The Kidney Doesn't Forgive: Drug Dosing Failures in Caribbean Renal and Liver Disease. ElesRx Clinical Reports, Report 2. Published 2026 at elesrx.com/reports/kidney-doesnt-forgive/. J.C. Epiphany Limited, Jamaica.

References

1. GBD 2023 CKD Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023. Lancet. 2025. doi:10.1016/S0140-6736(25)01853-7

2. Ferguson TS, Tulloch-Reid MK, Younger-Coleman NO, et al. The burden of chronic kidney disease and its major risk factors in Jamaica. Kidney Int. 2018;94(5):S27–S28. doi:10.1016/j.kint.2018.08.016

3. Cunningham-Myrie CA, et al. Chronic kidney disease in Jamaica: estimated prevalence and associated risk factors from the Jamaica Health and Lifestyle Survey III. medRxiv. 2025. doi:10.1101/2025.03.31.25324786

4. Waugh NR, et al. Prevalence of chronic kidney disease among patients attending a specialist diabetes clinic in Jamaica. West Indian Med J. 2013;62(7):632–637. PMC4763891

5. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi:10.1136/bmj.e8525